Pharmacology Watch – August 1, 2016
August 1, 2016
View Issues
-
CDC Advisory Committee Recommends Against Live Attenuated Influenza Vaccine
The decision came after a committee reviewed data showing vaccine effectiveness for the live attenuated influenza vaccine of only 3%.
-
Safe, Effective Alternatives to Warfarin
Non-vitamin K antagonist oral anticoagulants are safe and effective alternatives to warfarin in the routine care setting.
-
Drug May Slow Renal Disease Progression
In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal events than was placebo when added to standard care.
-
Good News for Type 2 Diabetics
The rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.
-
Patients Need More Education on Opioid Storage, Disposal
Recent survey discovers troubling trends.
-
FDA Actions
In this section: The FDA approves new chronic hepatitis C treatment, greenlights a treatment course for primary biliary cirrhosis, and strengthens warning about the risk of acute kidney injury in several diabetes medications.